Barclays’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $12.2M | Sell |
53,896
-181,040
| -77% | -$32.2M | ﹤0.01% | 1378 |
|
|
2026
Q1 | $40.5M | Buy |
234,936
+175,802
| +297% | +$32.6M | 0.01% | 801 |
|
|
2025
Q4 | $11.8M | Sell |
59,134
-92,225
| -61% | -$16.7M | ﹤0.01% | 1566 |
|
|
2025
Q3 | $23.7M | Sell |
151,359
-28,519
| -16% | -$4.53M | 0.01% | 1131 |
|
|
2025
Q2 | $27.3M | Buy |
179,878
+60,144
| +50% | +$8.02M | 0.01% | 964 |
|
|
2025
Q1 | $18M | Sell |
119,734
-7,038
| -6% | -$1.18M | 0.01% | 1092 |
|
|
2024
Q4 | $23.4M | Sell |
126,772
-4,054
| -3% | -$781K | 0.01% | 1040 |
|
|
2024
Q3 | $25.8M | Sell |
130,826
-34,379
| -21% | -$7.14M | 0.01% | 942 |
|
|
2024
Q2 | $34.1M | Buy |
165,205
+51,731
| +46% | +$11.7M | 0.01% | 748 |
|
|
2024
Q1 | $30.7M | Sell |
113,474
-55,722
| -33% | -$13.3M | 0.01% | 807 |
|
|
2023
Q4 | $40M | Sell |
169,196
-18,194
| -10% | -$3.58M | 0.01% | 767 |
|
|
2023
Q3 | $36.7M | Buy |
187,390
+38,620
| +26% | +$7.93M | 0.02% | 583 |
|
|
2023
Q2 | $31.3M | Buy |
148,770
+99,907
| +204% | +$19.9M | 0.02% | 592 |
|
|
2023
Q1 | $9.86M | Sell |
48,863
-17,913
| -27% | -$4.06M | ﹤0.01% | 1167 |
|
|
2022
Q4 | $14.6M | Sell |
66,776
-5,004
| -7% | -$1.09M | 0.01% | 1030 |
|
|
2022
Q3 | $14.1M | Sell |
71,780
-57,209
| -44% | -$12.4M | 0.02% | 729 |
|
|
2022
Q2 | $27.6M | Buy |
128,989
+15,100
| +13% | +$3.69M | 0.02% | 589 |
|
|
2022
Q1 | $32.3M | Buy |
113,889
+30,959
| +37% | +$9.55M | 0.03% | 537 |
|
|
2021
Q4 | $31.2M | Buy |
82,930
+5,569
| +7% | +$2.16M | 0.01% | 754 |
|
|
2021
Q3 | $31.9M | Buy |
77,361
+9,915
| +15% | +$4.12M | 0.01% | 694 |
|
|
2021
Q2 | $24.9M | Buy |
67,446
+54,480
| +420% | +$18.2M | 0.01% | 788 |
|
|
2021
Q1 | $3.76M | Buy |
12,966
+11,614
| +859% | +$3.23M | ﹤0.01% | 1758 |
|
|
2020
Q4 | $338K | Buy |
+1,352
| New | +$322K | ﹤0.01% | 3483 |
|
|
2020
Q3 | – | Sell |
-470
| Closed | -$82K | – | 5267 |
|
|
2020
Q2 | $82K | Buy |
+470
| New | +$75K | ﹤0.01% | 4644 |
|
|
2020
Q1 | – | Sell |
-8,393
| Closed | -$1.28M | – | 6180 |
|
|
2019
Q4 | $1.28M | Buy |
8,393
+4,000
| +91% | +$554K | ﹤0.01% | 3443 |
|
|
2019
Q3 | $582K | Sell |
4,393
-2,958
| -40% | -$397K | ﹤0.01% | 4126 |
|
|
2019
Q2 | $1.04M | Sell |
7,351
-22,513
| -75% | -$3.05M | ﹤0.01% | 3641 |
|
|
2019
Q1 | $4.34M | Sell |
29,864
-10,011
| -25% | -$1.32M | ﹤0.01% | 1767 |
|
|
2018
Q4 | $4.51M | Buy |
39,875
+8,480
| +27% | +$1.06M | ﹤0.01% | 1669 |
|
|
2018
Q3 | $4.22M | Sell |
31,395
-40,955
| -57% | -$5.05M | ﹤0.01% | 1991 |
|
|
2018
Q2 | $8.12M | Buy |
72,350
+18,128
| +33% | +$1.96M | 0.01% | 1375 |
|
|
2018
Q1 | $5.79M | Buy |
54,222
+35,163
| +184% | +$3.79M | ﹤0.01% | 1537 |
|
|
2017
Q4 | $2.09M | Buy |
19,059
+18,777
| +6,659% | +$2.04M | ﹤0.01% | 2386 |
|
|
2017
Q3 | $30K | Sell |
282
-775
| -73% | -$79.6K | ﹤0.01% | 5609 |
|
|
2017
Q2 | $107K | Sell |
1,057
-4,550
| -81% | -$419K | ﹤0.01% | 4845 |
|
|
2017
Q1 | $505K | Buy |
5,607
+4,362
| +350% | +$370K | ﹤0.01% | 3397 |
|
|
2016
Q4 | $96K | Sell |
1,245
-1,416
| -53% | -$108K | ﹤0.01% | 4776 |
|
|
2016
Q3 | $221K | Sell |
2,661
-12,736
| -83% | -$1.07M | ﹤0.01% | 3891 |
|
|
2016
Q2 | $1.27M | Sell |
15,397
-3,052
| -17% | -$251K | ﹤0.01% | 2392 |
|
|
2016
Q1 | $1.38M | Buy |
18,449
+2,847
| +18% | +$211K | ﹤0.01% | 2261 |
|
|
2015
Q4 | $1.25M | Sell |
15,602
-655
| -4% | -$47.2K | ﹤0.01% | 2402 |
|
|
2015
Q3 | $1.02M | Buy |
16,257
+14,699
| +943% | +$1.06M | ﹤0.01% | 2681 |
|
|
2015
Q2 | $109K | Buy |
1,558
+626
| +67% | +$46.3K | ﹤0.01% | 4602 |
|
|
2015
Q1 | $74K | Sell |
932
-1,261
| -58% | -$93K | ﹤0.01% | 5024 |
|
|
2014
Q4 | $138K | Sell |
2,193
-3,657
| -63% | -$229K | ﹤0.01% | 4928 |
|
|
2014
Q3 | $345K | Sell |
5,850
-8,532
| -59% | -$488K | ﹤0.01% | 4278 |
|
|
2014
Q2 | $762K | Buy |
14,382
+191
| +1% | +$10.5K | ﹤0.01% | 3586 |
|
|
2014
Q1 | $851K | Buy |
14,191
+1,252
| +10% | +$73K | ﹤0.01% | 3409 |
|
|
2013
Q4 | $688K | Sell |
12,939
-16,247
| -56% | -$816K | ﹤0.01% | 3778 |
|
|
2013
Q3 | $1.34M | Buy |
29,186
+21,787
| +294% | +$1,000K | ﹤0.01% | 3033 |
|
|
2013
Q2 | $303K | Buy |
+7,399
| New | +$317K | ﹤0.01% | 4765 |
|
Other funds holding CRL
AI
Barclays's CRL Position: Q2 2026 in Review
Barclays reduced its Charles River Laboratories (CRL) stake by 77% in Q2 2026, selling an estimated $32.2M and leaving 53,896 shares worth $12.2M. The position accounts for ﹤0.01% of the portfolio, ranked #1378.
Barclays first reported a position in CRL in Q2 2013 and has held it in 51 quarters since. The position peaked at $40.5M in Q1 2026. 570 funds tracked by Wall St. Rank hold CRL as of Q2 2026.
- Barclays held 53,896 shares of Charles River Laboratories worth $12.2M as of Q2 2026.
- Barclays sold 181,040 Charles River Laboratories shares in Q2 2026, an estimated $32.2M.
- Charles River Laboratories made up ﹤0.01% of Barclays's portfolio in Q2 2026, its #1378 holding.
- Barclays first reported a position in Charles River Laboratories in Q2 2013 and has held it in 51 quarters since.
- Barclays's Charles River Laboratories position peaked at $40.5M in Q1 2026.
- 570 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.
Based on Barclays's 13F filing for Q2 2026, filed 14 Aug 2026.